Structural investigation of the alpha-1-antichymotrypsin: Prostate-specific antigen complex by comparative model building

Protein Science

Volumn 5, Issue 5, 1996, Pages 836-851

  Villoutreix, Bruno O ^a   Lilja, Hans ^b   Pettersson, Kim ^c   Lövgren, Timo ^c   Teleman, Olle ^a  

^a VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Antichymotrypsin; Coagulation; Electrostatic potential; Human glandular kallikrein 1; Prostate cancer; Prostate specific antigen; Protein C; Protein c inhibitor; Protein modeling; Serine protease; Serpin

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; KALLIKREIN; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROSTATE SPECIFIC ANTIGEN; PROTEIN C; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR;

AMINO ACID SUBSTITUTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING SITE; BLOOD CLOTTING; COMPLEX FORMATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; STRUCTURE ANALYSIS;

ALPHA 1-ANTICHYMOTRYPSIN; AMINO ACID SEQUENCE; BINDING SITES; HEPARIN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROSTATE-SPECIFIC ANTIGEN; PROTEIN BINDING; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; SERINE PROTEINASE INHIBITORS;

EID: 0029983596     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1002/pro.5560050505     Document Type: Article

References (91)

1. Akiyama K, Nakamura T, Iwanaga S, Hara M. 1987. The chymotrypsinlike activity of human prostate-specific antigen, γ-seminoprotein. FEBS Lett 225:168-172.
2. Bartunik HD, Summers LJ, Bartsch HH. 1989. Crystal structure of bovine β-trypsin at 1.5 Å resolution in a crystal form with low molecular packing density. Active site geometry, ion pairs and solvent structure. J Mol Biol 210:813-828.
3. a values of ionizable groups in bacteriorhodopsin. J Mol Biol 224:473-486.
4. 1 -antichymotrypsin at 2.7 Å resolution. J Mol Biol 218:595-606.
5. Bélanger A, van Halbeek H, Graves HCB, Granbois K, Stamey TA, Huang L, Poppe I, Labrie F. 1995. Molecular mass and carbohydrate structure of prostate specific antigen: Studies for the establishment of an international PSA standard. The Prostate 27:187-197.
6. Bernstein FC, Koetzle TF, Williams GJB, Meyer EF Jr, Brice MD, Rodgers JR, Kennard O, Shimanouchi T, Tasmui M. 1977. The Protein Data Bank: A computer-based archival file for macro-molecular structures. J Mol Biol 112:535-542.
7. Blevins RA, Tulinsky A. 1985. The refinement and the structure of the dimer of α-chymotrypsin at 1.67 Å resolution. J Biol Chem 260:4264-4275.
8. Blundell TL, Sibanda BL, Sternberg MJE, Thornton JM. 1987. Knowledge-based prediction of protein structures and design of novel molecule. Nature 326:341-352.
9. Bode W. 1979. The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. J Mol Biol 127:357-374.
10. Bode W, Chen Z, Bartels K, Kutzbach C, Schmidt-Kastner G, Bartunik H. 1983. Refined 2 Å X-ray crystal structure of porcine pancreatic kallikrein A, a specific trypsin-like serine proteinase. J Mol Biol 164:231-282.
11. Bode W, Huber R. 1991. Ligand binding: Proteinase-protein inhibitor interactions. Curr Opin Struct Biol 1:45-52.
12. Bode W, Huber R. 1992. Natural protein proteinase inhibitors and their interaction with proteinases. Eur J Biochem 204:433-451.
13. Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. 1989. The refined 1.9 Å crystal structure of human α-thrombin: Interactions with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 8:3467-3475.
14. Bode W, Turk D, Karshikov A. 1992. The refined 1.9 Å X-ray structure of D-Phe-Pro-Arg chloromethylketone-innibited human α-thrombin. Protein Sci 1:426-411.
15. Bridon DP, Dowell BL. 1995. Structural comparison of prostate-specific antigen and human glandular kallikrein using molecular modeling. Urology 45:801-806.
16. Brillard-Bourdet M, Moreau T, Gauthier F. 1995. Substrate specificity of tissue kallikreins: Importance of an extended interaction site. Biochim Biophys Acta 1246:41-52.
17. Carrell RW, Stein PE, Fermi G, Wardell MR. 1994. Biological implications of a 3 Å structure of dimeric antithrombin. Structure 2:257-270.
18. Chen Z, Bode W. 1983. Refined 2.5 Å X-ray crystal structure of the complex formed by porcine kallikrein A and the bovine pancreatic trypsin inhibitor. J Mol Biol 164:283-311.
19. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150:100-105.
20. Christensson A, Laurell CB, Lilja H. 1990. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194:755-763.
21. Christensson A, Lilja H. 1994. Complex formation between protein C inhibitor and prostate specific antigen in vitro and in human plasma. Eur J Biochem 220:45-53.
22. Clements JA, Mukthar A. 1994. Glandular kallikreins and the prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 78:1536-1539.
23. Cohen FE, Gregoret LM, Amiri P, Aldape K, Railey J, McKerrow JH. 1991. Arresting tissue invasion of a parasite by protease inhibitors chosen with the aid of computer modeling. Biochemistry 30:11221-11229.
24. Cooper ST, Whinna HC, Jackson TP, Boyd JM, Church FC. 1995. Intermolecular interactions between protein C inhibitor and coagulation proteases. Biochemistry 34:12991-12997.
25. España F, Gilabert J, Estelles A, Romeu A, Aznar J, Cabo A. 1991. Functionally active protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs ai high concentrations in human seminal plasma and complexes with prostate-specific antigen. Thromb Res 64:309-320.
26. España F, Sanches-Cuenca J, Vera CD, Estelles A, Gilabert J. 1993. A quantitative ELISA for the measurement of complexes of prostate-specific antigen with protein C inhibitor when using a purified standard. J Lab Clin Med 122:711-719.
27. Fernández JA, Villoutreix BO, Hackeng TM, Griffin JH, Bouma BN. 1994. Analysis of protein S C4b-binding protein interactions by homology modeling and inhibitory antibodies. Biochemistry 33:11073-11078.
28. Fisher CL, Greengard JS, Griffin JH. 1994. Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen. Protein Sci 3:58-599.
29. Frigerio F, Coda A, Pugliese C, Lionetti C, Menegatti E, Amiconi G, Schnebli HP, Ascenzi P, Bolognesi M. 1992. Crystal and molecular structure of the bovine α-chymotrypsin-eglin C complex at 2.0 Å resolution. J Mol Biol 225:107-123.
30. Fujinaga M, James MNG. 1987. Rat submaxillary gland serine protease, Tonin, structure solution and refinement at 1.8 Å resolut ion. J Mol Biol 195: 373-396.
31. Fujinaga M, Sielecki AR, Read RJ, Ardelt W, Laskowski M Jr, James MNG. 1987. Crystal and molecular structures of the complex α-chymotrypsin with its inhibitor turkey ovomucoid third domain at 1.8 Å resolution. J Mol Biol 195:397-418.
32. Furie B, Bing DH, Feldmann RJ, Robinson DJ, Burnier JP, Furie BC. 1981. Computer-generated models of blood coagulation factor Xa, factor IXa, and thrombin based upon structural homology with other serine proteases. J Biol Chem 257:3875-3882.
33. Gilson M, Sharp K, Honig B. 1987. Calculating the electrostatic potential for molecules in solution. J Comput Chem 9:327-335.
34. Greengard JS, Fisher CL, Villoutreix B, Griffin JH. 1994. Structural basis for type I and type II deficiencies of antithrombotic plasma protein C: Patterns revealed by three-dimensional molecular modeling of mutations of the protease domain. Proteins Struct Fund Genet 18:367-380.
35. Greer J. 1981. Model of a specific interaction. J Mol Biol 153:1043-1053.
36. Greer J. 1990. Comparative modeling methods: Application to the family of the mammalian serine proteases. Proteins Struct Funct Genet 7:317-334.
37. Haglcr AT, Huler E, Lifson S. 1974. Energy functions for peptides and proteins. I. Derivation of a consistent force field including the hydrogen bond from amide crystals. J Am Chem Soc 96:5319-5327.
38. Hagler AT, Lifson S. 1974. Energy functions for peptides and proteins. II. The amide hydrogen bond and calculation of amide crystal properties. J Am Chem Soc 96:5327-5335.
39. Harvey S. 1989. Treatment of electrostatic effects in macromolecular modeling. Proteins Struct Funct Genet 5:78-92.
40. Hedstrom L, Szilagyi L, Rutter WJ. 1992. Converting to chymotrypsin: The role of surface loops. Science 255:1249-1253.
41. Henttu P, Lukkarinen O, Vihko P. 1990. Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int J Cancer 45:654-660.
42. Honig B, Nicholls A. 1995. Classical electrostatics in biology and chemistry. Science 268:1144-1149.
43. 1-antitrypsin for structure and functions of serpins. Biochemistry 23:8951-8966.
44. Insight II, DelPhi, Homology, Discover. San Diego, California: Biosym-MSI.
45. Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. 1980. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 255:10081-10090.
46. Karshikoff A, Bode W, Tulinsky A, Stone SR. 1992. Electrostatic interactions in the association of proteins: An analysis of thrombin-hirudin complex. Protein Sci 1.727-735.
47. Katz DS, Christianson DW. 1993. Modeling the uncleaved serpin antichymotrypsin and its chymotrypsin complex. Protein Eng 6:701-709. Klapper I, Hagstrom R, Fine R, Sharp K,
48. Honig B. 1986. Focusing of electric fields in the active site of Cu-Zn superoxide dismutase: Effects of ionic strength and amino-acid modification. Proteins Struct Funct Genet 1:47-59.
49. Kuhn LA, Griffin JH, Fisher CL, Greengard JS, Bouma BN, Espana F, Tainer JA. 1990. Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor. Proc Natl Acad Sci 87:8506-8510.
50. Le Bonniec BF, Guinto ER, Stone SR. 1995. Identification of thrombin residues that modulate its interactions with antithrombin III and α 1-antitrypsin. Biochemistry 34:12241-12248.
51. Lee B, Richards FM. 1971. The interpretation of protein structure: Estimation of static accessibility. J Mol Biol 55:379-400.
52. 1-antichymotrypsin. Clin Chem 39:2098-2103.
53. Lilja H, Abrahamsson PA, Lundwall Å. 1989. Semenogelin, the predominant protein in human semen. J Biol Chem 254:1894-1900.
54. 1-antichymotrypsin. Clin Chem 37: 1618-1625.
55. 1-proteinase inhibitor. J Mol Biol 177:531-536.
56. Lovgren J, Piironen T, Övermo C, Dowell B, Karp M, Pettersson K, Lilja H, Lundwall Å. 1995. Production of recombinant PSA and hK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun 213:888-895.
57. Lundwall Ä, Lilja H. 1987. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 214:317-322.
58. Madison EL, Goldsmith EJ, Gerard RD, Gething MJH, Sambrook JF. 1989. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature 339:721-124.
59. Madison EL, Goldsmith EJ, Gething MJH, Sambrook JF, Gerard RD. 1990. Restoration of serine protease-inhibitor interaction by protein engineering. J Biol Chem 265:21423-21426.
60. Meyer E, Cole G, Radhakrishnan R, Epp O. 1988. Structure of native porcine pancreatic elastase at 1.65 Å resolution. Acta Crystallogr B 44:26-38.
61. Monne M, Croce CM, Yu H, Diamandis EP. 1994. Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. Cancer Res 54:6344-6347.
62. Oesterling JE. 1991. Prostate-specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923.
63. Perona JJ, Craik CS. 1995. Structural basis of substrate specificity in the serine proteases. Protein Sci 4:337-360.
64. 1-antichymotrypsin complex. Clin Chem 41:1-9.
65. Ponder JW, Richards FM. 1987. Tertiary templates for proteins: Use of packing criteria in the enumeration of allowed sequences for different structural classes. J Mol Biol 193:775-791.
66. Radtke KP, Fernández JA, Villoutreix BO, Greengard JS, Griffin JH. 1995. Characterization of a cDNA for Rhesus monkey protein C inhibitor. Evidence for N-terminal involvement in heparin stimulation. Thromb Haemost 74:1079-1087.
67. Riegman PHJ, Vliestra RJ, Suurmeijer J, Cleutjens CBJM, Trapman J. 1992. Characterization of the human kallikrein locus. Genomics 14:6-11.
68. Schaller J, Akiyama K, Tsuda R, Hara M, Marti T, Rickli E. 1987. Isolation, characterization and amino-acid sequence of gamma-seminoprotein, a glycoprotein from human seminal plasma. Eur J Biochem 170:111-120.
69. Schechter I, Berger A. 1967. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27:157-162.
70. Schedlich LJ, Bennetts B, Morris BJ. 1987. Primary structure of a human glandular kallikrein gene. DNA 6:429-437.
71. Schreuder HA, de Boer B, Dijkema R, Mulders J, Theunissen HJM, Grootenhuis PDJ, Hol WG. 1994. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nature Struct Biol 1:48-54.
72. Sharp K, Honig B. 1990. Electrostatic interactions in macromolecules: Theory and applications. Annu Rev Biophys Chem 19:301-332.
73. Sheehan JP, Sadler JE. 1994. Molecular mapping of the heparin-binding exosite of thrombin. Proc Natl Acad Sci USA 91:5518-5522.
74. Shenkin PS, Yarmush DL, Fine RM, Wang H, Levinthal C 1987. Predicting antibody hypervariable loop conformation I. Ensembles of random conformations for ringlike structures. Biopolymers 26:2053-2085.
75. Shirk RA, Elisen MGLM, Meijers JCM, Church FC. 1994. Role of the H helix in heparin binding to protein C inhibitor. J Biol Chem 269:28690-28695.
76. Spassov VZ, Karshikov AD, Atanasov BP. 1989. Electrostatic interactions in proteins. A theoretical analysis of lysozyme ionization. Biochim Biophys Acta 999:1-6.
77. Stein PE, Leslie AG, Finch JT, Turnell WG, Mc Laughlin P J, Carrell RW. 1990. Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature 347:99-102
78. Stein PE, Leslie AGW, Finch JT, Carrell RW. 1991 Crystal structure of uncleaved ovalbumin at 1.95 Å resolution. J Mol Biol 221:941-959.
79. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer. Cancer Res 51:222-226.
80. Struthers RS, Kitson DH, Hagler AT. 1991. Predicted three-dimensional structure of the protease inhibitor domain of the Alzheimer's disease β-amyloid precursor. Proteins Struct Fund Genet 9:1-11.
81. 2+-free GLA domain sheds light on membrane binding of blood coagulation proteins. Nature Struct Biol 2:504-509.
82. Suzuki K, Nishioka J, Hashimoto S. 1983. Protein C inhibitor: Purification from human plasma and characterization. J Biol Chem 258:163-168.
83. Vihinen M. 1994. Modeling of prostate specific antigen and human glandular kallikrein structures. Biochem Biophys Res Commun 204:1251-1256.
84. Villoutreix BO, Getzoff ED, Griffin JH. 1994a. A structural model for the prostate disease marker prostate-specific antigen. Protein Sci 3:2033-2044.
85. Villoutreix BO, Spassov VZ, Atanasov BP, Herve G, Ladjimi MM. 1994b. Structural modeling and electrostatic properties of aspartate transcarbamylase from Saccharomyces cerevisiae. Proteins Struct Funct Genet 19:230-243.
86. Warshel A, Åqxist J. 1991. Electrostatic energy and macromolecular function. Annu Rev Biophys Biophys Chem 20:267-298.
87. Wati KWK, Lee PJ, Timkulu TM, Chan WP, Loor R. 1986. Human prostate-specific antigen: Structural and functional similarity with serine protease. Proc Natl Acad Sci USA 83:3166-3170.
88. Wei A, Rubin H, Cooperman BS, Christianson DW. 1994. Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop. Nature Struct Biol 1:251-258.
89. Wright HT, Qian HX, Huber R. 1990. Crystal structure of plakalbumin, a proteolyticaily nicked form of ovalbumin. J Mol Biol 213:513-528.
90. Young CYF, Andrews PE, Montgomery BT, Tindall DJ. 1992. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 31:818-824.
91. Yu H, Diamandis EP. 1995. Prostate specific antigen in milk of lactating women. Clin Chem 41:54-58.